Daily Judi: Wednesday, March 29, 2023
Every day we scan the headlines for the best items that engage the clinical trial ecosystem, workflow solutions, and more—all the latest news you need to know. Here are today's stories:
Today, the U.S. Food and Drug Administration announced it has approved Narcan nasal spray for over-the-counter, nonprescription use.
Considering diversity action plans required by the Food and Drug Omnibus Reform Act of 2022, Adam Bluestein reports on new startups whose mission is to increase diversity and inclusion in clinical trials. (Fast Company)
Kim Yun-mi examines the emergence of global decentralized clinical trials to reduce drug development time and expense, and improve patient access, and asks, "What about Korea?" (Korea Biomedical Review)
Our Culture
“Dossiers and redaction are built within the Judi platform, which helps significantly with adjudication management—and the client collaborates on the process.”
–Jess, Program Manager
About Judi
Judi speeds and improves the world's clinical trial workflows. Our cloud-based platform has 133,000 users across 171 countries. We eliminate the chaos so clinical teams can focus on the patient, rather than the process. We are a SOC 2 certified collaboration platform.
